Recombinant Biotinylated Cynomolgus BCMA / TNFRSF17 Protein, Fc Tag, Avi Tag (Avitag™), 25 µg

Background
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is also known as B-cell maturation protein (BCMA), CD antigen CD269, which is a member of the TNF-receptor superfamily. TNFRSF17 contains one TNFR-Cys repeat. TNFRSF17 is expressed in mature B-cells, but not in T-cells or monocytes. TNFRSF17 is receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. TNFRSF17 promotes B-cell survival and plays a role in the regulation of humoral immunity. TNFRSF17 can activate NF-kappa-B and JNK.

Source
Recombinant Biotinylated Cynomolgus / Rhesus macaque BCMA, Fc,Avitag (BCA-C82F4) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Ala 53 (Accession # A0A2K5UD97-1 ). In the region Met 1 - Ala 53, the AA sequence of Cynomolgus and Rhesus macaque BCMA are homologus.
Predicted N-terminus: Met 1

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 33.9 kDa. The protein migrates as 42-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.
 
Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Safety and efficacy of BCMA CAR-T cell therapy in older patients with multiple myeloma"
Reyes, Huang, Lo et al
Transplant Cell Ther (2023)
(2) "Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results"
Mailankody, Matous, Chhabra et al
Nat Med (2023)
(3) "Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis"
Wäsch, Strüssmann, Wehr et al
Ann Hematol (2023)
Showing 1-3 of 1045 papers.